Lee S. Schwartzberg, MD, on HR+ Breast Cancer: Treatment Trial Results
2017 San Antonio Breast Cancer SymposiumLee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).
Related Videos
Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial
Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or doceta...
Joseph A. Sparano, MD, on Stage II–III Breast Cancer and CTCs
Joseph A. Sparano, MD, of Montefiore Medical Center/Albert Einstein College of Medicine, discusses findings that suggest circulating tumor cells 5 years after diagnosis are prognos...
Eric S. Winer, MD, on Metastatic Breast Cancer: Debate on a Research Tool
Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-...
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients ...
SABCS 40th Anniversary Award Lecture: Richard Pazdur, MD, on Cancer Drug Development
Richard Pazdur, MD, of the U.S. Food & Drug Administration’s Oncology Center of Excellence, discusses the rapid changes in evaluating and approving new and effective agents, in...
